Ammar Muhammad

760 total citations
26 papers, 395 citations indexed

About

Ammar Muhammad is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Ammar Muhammad has authored 26 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Surgery and 7 papers in Epidemiology. Recurrent topics in Ammar Muhammad's work include Pituitary Gland Disorders and Treatments (15 papers), Growth Hormone and Insulin-like Growth Factors (11 papers) and Adrenal and Paraganglionic Tumors (10 papers). Ammar Muhammad is often cited by papers focused on Pituitary Gland Disorders and Treatments (15 papers), Growth Hormone and Insulin-like Growth Factors (11 papers) and Adrenal and Paraganglionic Tumors (10 papers). Ammar Muhammad collaborates with scholars based in Netherlands, Pakistan and Indonesia. Ammar Muhammad's co-authors include Sebastian Neggers, A. J. van der Lely, J. A. M. J. L. Janssen, Eva C Coopmans, Patric J. D. Delhanty, A.H.G. Dallenga, Iain Haitsma, Aart Jan van der Lely, Leo J. Hofland and Federico Gatto and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Clinical Endocrinology & Metabolism and Journal of the American College of Surgeons.

In The Last Decade

Ammar Muhammad

18 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ammar Muhammad Netherlands 11 328 168 83 48 30 26 395
Rosália do Prado Padovani Brazil 10 281 0.9× 154 0.9× 30 0.4× 21 0.4× 12 0.4× 27 347
Nami Takada Japan 11 160 0.5× 102 0.6× 37 0.4× 28 0.6× 31 1.0× 24 277
Iraklis Vainas Greece 11 231 0.7× 138 0.8× 89 1.1× 7 0.1× 14 0.5× 18 337
Monica Hollowell United States 10 224 0.7× 189 1.1× 21 0.3× 14 0.3× 38 1.3× 21 393
Maria Cristina Giustiniani Italy 9 87 0.3× 156 0.9× 37 0.4× 15 0.3× 58 1.9× 26 276
Miguel Paja Spain 9 234 0.7× 139 0.8× 28 0.3× 6 0.1× 16 0.5× 21 309
Peter P. Issa United States 9 165 0.5× 131 0.8× 24 0.3× 12 0.3× 13 0.4× 43 277
G Kullmann Norway 6 156 0.5× 114 0.7× 53 0.6× 15 0.3× 39 1.3× 9 304
Jorge Rosa Santos Portugal 11 220 0.7× 159 0.9× 76 0.9× 12 0.3× 35 1.2× 17 375
Steven A. De Jong United States 7 215 0.7× 147 0.9× 44 0.5× 6 0.1× 79 2.6× 12 360

Countries citing papers authored by Ammar Muhammad

Since Specialization
Citations

This map shows the geographic impact of Ammar Muhammad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ammar Muhammad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ammar Muhammad more than expected).

Fields of papers citing papers by Ammar Muhammad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ammar Muhammad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ammar Muhammad. The network helps show where Ammar Muhammad may publish in the future.

Co-authorship network of co-authors of Ammar Muhammad

This figure shows the co-authorship network connecting the top 25 collaborators of Ammar Muhammad. A scholar is included among the top collaborators of Ammar Muhammad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ammar Muhammad. Ammar Muhammad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muhammad, Ammar, et al.. (2025). Bone Metastasis Disease from Mucinous Carcinoma of the Breast. 4(1). 36–40.
2.
3.
Muhammad, Ammar, et al.. (2024). Late complications following infant male circumcision using Plastibell technique: Experience from a single facility in Pakistan. SHILAP Revista de lepidopterología. 8. 100171–100171.
4.
5.
Muhammad, Ammar, et al.. (2021). Implementation of an infant male circumcision programme, Pakistan. Bulletin of the World Health Organization. 99(4). 250–258. 5 indexed citations
6.
Coopmans, Eva C, Jan Frystyk, Nils E. Magnusson, et al.. (2020). Soluble Klotho: a possible predictor of quality of life in acromegaly patients. Endocrine. 69(1). 165–174. 13 indexed citations
7.
Coopmans, Eva C, Ammar Muhammad, Adrian Daly, et al.. (2020). The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study. Endocrine. 68(3). 640–649. 3 indexed citations
8.
Coopmans, Eva C, J.J. Schneiders, Nicole S. Erler, et al.. (2020). T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. European Journal of Endocrinology. 182(6). 595–605. 31 indexed citations
9.
Muhammad, Ammar, et al.. (2020). Assessment of Trauma Care Capacity in Karachi, Pakistan: A Step towards an Integrated Trauma Care System in a Developing Country. Journal of the American College of Surgeons. 231(4). e26–e27.
10.
Coopmans, Eva C, Ammar Muhammad, A. J. van der Lely, J. A. M. J. L. Janssen, & Sebastian Neggers. (2019). How to Position Pasireotide LAR Treatment in Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 104(6). 1978–1988. 39 indexed citations
11.
12.
Muhammad, Ammar, Eva C Coopmans, Federico Gatto, et al.. (2018). Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. The Journal of Clinical Endocrinology & Metabolism. 104(3). 915–924. 42 indexed citations
13.
Muhammad, Ammar, Eva C Coopmans, Patric J. D. Delhanty, et al.. (2018). Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. European Journal of Endocrinology. 179(5). 269–277. 46 indexed citations
14.
Muhammad, Ammar, A. J. van der Lely, Patric J. D. Delhanty, et al.. (2017). Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). The Journal of Clinical Endocrinology & Metabolism. 103(2). 586–595. 66 indexed citations
15.
Muhammad, Ammar, et al.. (2017). The Acylated/Unacylated Ghrelin Ratio Is Similar in Patients With Acromegaly During Different Treatment Regimens. The Journal of Clinical Endocrinology & Metabolism. 102(7). 2425–2432. 2 indexed citations
16.
Muhammad, Ammar, A. J. van der Lely, Patric J. D. Delhanty, et al.. (2016). What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?. European Journal of Endocrinology. 174(5). 663–667. 10 indexed citations
17.
Muhammad, Ammar, Sebastian Neggers, & A. J. van der Lely. (2016). Pregnancy and acromegaly. Pituitary. 20(1). 179–184. 24 indexed citations
18.
Ajeganova, Sofia, Jennifer Humphreys, Chikashi Terao, et al.. (2016). Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Research & Therapy. 18(1). 285–285. 48 indexed citations
19.
Muhammad, Ammar, et al.. (2015). Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Endocrine. 52(2). 206–213. 26 indexed citations
20.
Neggers, Sebastian, Ammar Muhammad, & Aart Jan van der Lely. (2015). Pegvisomant Treatment in Acromegaly. Neuroendocrinology. 103(1). 59–65. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosália do Prado Padovani Breakdown of academic impact, for papers by Nami Takada Breakdown of academic impact, for papers by Iraklis Vainas Breakdown of academic impact, for papers by Monica Hollowell Breakdown of academic impact, for papers by Maria Cristina Giustiniani Breakdown of academic impact, for papers by Miguel Paja Breakdown of academic impact, for papers by Peter P. Issa Breakdown of academic impact, for papers by G Kullmann Breakdown of academic impact, for papers by Jorge Rosa Santos Breakdown of academic impact, for papers by Steven A. De Jong
Rankless by CCL
2026